The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis

BACKGROUND: Many patients with relapsing-remitting multiple sclerosis (MS) treated with high-dose interferon-β (IFNβ) develop serum binding antibodies (BAb) and neutralizing antibodies (NAb). NAb reduces the biological activity of IFNβ, which contributes to clinical failure in these patients. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Edward, Green, Barbara, Markowitz, Clyde, Murray, Ronald, Goodman, Andrew D, Glenski, Stephen J, Loupe, Pippa, Cogburn, Jo Nita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994206/
https://www.ncbi.nlm.nih.gov/pubmed/24708578
http://dx.doi.org/10.1186/1471-2377-14-73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994206/
https://www.ncbi.nlm.nih.gov/pubmed/24708578
http://dx.doi.org/10.1186/1471-2377-14-73

Ejemplares similares